It was previously shown that patients with NAT2 slow acetylator genotypes (homozygous for NAT*5, NAT*6, and NAT2*7 alleles) are significantly (P < 0.002) more prone to develop UADT cancer (0.37) as compared with controls (0.22) [133]. This evidence concerns the gene BRD2 and cancer.